Stock listing
CABA Stock Price, News, Filings & Events — Cabaletta Bio, Inc.
Selected listing: CABA · BOATS · USD · US
This page tracks Cabaletta Bio, Inc.'s CABA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CABA:BOATS. CABA:BOATS is the stock-level entry point for investors researching Cabaletta Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Cabaletta Bio, Inc. is a public biotechnology company based in the United States, focused on developing innovative cell therapies for autoimmune diseases. The company is traded under the ticker symbol CABA and has a market capitalization of approximately $438.6 million. Cabaletta Bio is committed to advancing its research and development efforts in the field of immunotherapy.

- Ticker
- CABA:BOATS
- Asset type
- Stock
- Market cap
- $529.0M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
Cabaletta Bio, Inc. CABA:BOATS stock context
This page tracks Cabaletta Bio, Inc.'s CABA:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CABA:BOATS. CABA:BOATS is the stock-level entry point for investors researching Cabaletta Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Cabaletta Bio, Inc. is a public biotechnology company based in the United States, focused on developing innovative cell therapies for autoimmune diseases. The company is traded under the ticker symbol CABA and has a market capitalization of approximately $438.6 million. Cabaletta Bio is committed to advancing its research and development efforts in the field of immunotherapy.
Latest news from Cabaletta Bio, Inc.
Cabaletta Bio to Participate in Upcoming Investor Conferences
September 1, 2026
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus ...
June 3, 2026
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
May 4, 2026
Cabaletta Bio, Inc. earnings calls
Research Cabaletta Bio, Inc.
Cabaletta Bio, Inc. investor report
Review AI stock analysis and investor report context for CABA:BOATS.
Cabaletta Bio, Inc. company profile
View the public company page for Cabaletta Bio, Inc. on 6ix.
Cabaletta Bio, Inc. news
Read company news and market updates connected to Cabaletta Bio, Inc..
Cabaletta Bio, Inc. investor events
Find investor webinars, events, and replay context for Cabaletta Bio, Inc..
Alternate listings
CABA:NASDAQ
US · USD
Alternate listing for Cabaletta Bio, Inc.; the primary context on this page is CABA:BOATS.
CABA:BMV
MX · MXN
Alternate listing for Cabaletta Bio, Inc.; the primary context on this page is CABA:BOATS.
CABA:BIVA
MX · MXN
Alternate listing for Cabaletta Bio, Inc.; the primary context on this page is CABA:BOATS.